Syndax Raises $40 Million Series A

Syndax Inc., a Waltham, Mass.-based drug company focused on cancer therapies in mechanistically-driven combination regimens, has raised $40 million in Series A funding. Domain Associates and MPM Capital co-led the deal, and were joined by Avalon Ventures, Forward Ventures and Pappas Ventures. The company was co-founded by Eckard Weber of Domain and Ronald Evans of the Salk Institute for Biological Studies and the Howard Hughes Medical Institute.